4162.TWO
PharmaEngine, Inc. [4162.TWO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4162.TWO Stock Summary
Top 10 Correlated Stocks
4162.TWO
In the News
4162.TWO Financial details
Company Rating
Buy
Market Cap
13.95B
Income
274.65M
Revenue
767.67M
Book val./share
26.9
Cash/share
25.26
Dividend
2
Dividend %
1.96%
Employees
17
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
50.58
Forward P/E
-
PEG
-36.22
P/S
19.83
P/B
3.85
P/C
3.52
P/FCF
67.4
Quick Ratio
56.93
Current Ratio
61.92
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
1.91
EPS next Y
-
EPS next Q
-
EPS this Y
-13.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
45.79%
Revenue last 5Y
19.57%
Revenue Q/Q
-23.83%
EPS Q/Q
-53.57%
-
-
-
-
SMA20
-
SMA50
-6.86%
SMA100
-11.21%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
8%
ROC
0.09%
Gross Margin
93%
Oper. Margin
46%
Profit Margin
39%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
79.8-122.5
52W High
-27.05%
52W Low
+12.66%
RSI
35
Rel Volume
0.63
Avg Volume
1.53M
Volume
958.32K
Perf Week
-9.92%
Perf Month
-9.28%
Perf Quarter
-1.87%
Perf Half Y
-1.44%
-
-
-
-
Beta
0.717
-
-
Volatility
2.93%, 2.96%
Prev Close
-4.91%
Price
89
Change
-3.68%
4162.TWO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.16 | 7.25 | 4.53 | 4.56 | 5.35 | |
| Net income per share | 0.29 | 4.15 | 2.95 | 2.22 | 1.91 | |
| Operating cash flow per share | 0.11 | 0.44 | 6.43 | 1.41 | 1.79 | |
| Free cash flow per share | 0.11 | 0.44 | 6.43 | 1.38 | 1.78 | |
| Cash per share | 23.44 | 23.3 | 26.39 | 25.5 | 25.26 | |
| Book value per share | 23.91 | 27.54 | 27.25 | 26.97 | 26.9 | |
| Tangible book value per share | 23.9 | 27.54 | 27.25 | 26.95 | 26.9 | |
| Share holders equity per share | 23.91 | 27.54 | 27.25 | 26.97 | 26.9 | |
| Interest debt per share | 0.23 | 0.15 | 0.05 | 0.16 | 0.11 | |
| Market cap | 9.98B | 8.43B | 10.49B | 17.95B | 15.8B | |
| Enterprise value | 9.92B | 6.62B | 8.35B | 16.2B | 14.94B | |
| P/E ratio | 234.53 | 13.95 | 24.63 | 56.31 | 57.52 | |
| Price to sales ratio | 31.78 | 7.98 | 16.02 | 27.43 | 20.58 | |
| POCF ratio | 620.69 | 130.18 | 11.29 | 88.85 | 61.47 | |
| PFCF ratio | 628.82 | 131.41 | 11.29 | 90.62 | 61.7 | |
| P/B Ratio | 2.87 | 2.1 | 2.66 | 4.64 | 4.09 | |
| PTB ratio | 2.87 | 2.1 | 2.66 | 4.64 | 4.09 | |
| EV to sales | 31.59 | 6.27 | 12.75 | 24.76 | 19.46 | |
| Enterprise value over EBITDA | 175.62 | 8.65 | 15.03 | 40.39 | 52.19 | |
| EV to operating cash flow | 616.99 | 102.18 | 8.98 | 80.21 | 58.12 | |
| EV to free cash flow | 625.08 | 103.15 | 8.98 | 81.8 | 58.34 | |
| Earnings yield | 0 | 0.07 | 0.04 | 0.02 | 0.02 | |
| Free cash flow yield | 0 | 0.01 | 0.09 | 0.01 | 0.02 | |
| Debt to equity | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Debt to assets | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Net debt to EBITDA | -1.05 | -2.37 | -3.86 | -4.35 | -3.01 | |
| Current ratio | 25.85 | 22.61 | 45.71 | 49.86 | 46.78 | |
| Interest coverage | 444.46 | 1.7K | 2.57K | 5.1K | 894.14 | |
| Income quality | 0.32 | 0.09 | 1.7 | 0.51 | 0.94 | |
| Dividend Yield | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | |
| Payout ratio | 3.42 | 0.12 | 0.85 | 1.22 | 1.05 | |
| Sales general and administrative to revenue | 0.27 | 0.07 | 0.12 | 0.15 | 0.12 | |
| Research and developement to revenue | 0.42 | 0.09 | 0.21 | 0.28 | 0.4 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.01 | -0.01 | 0 | -0.02 | 0 | |
| Capex to revenue | 0 | 0 | 0 | -0.01 | 0 | |
| Capex to depreciation | -0.03 | -0.05 | -0.02 | -0.46 | -0.11 | |
| Stock based compensation to revenue | 0.02 | 0 | 0 | 0 | 0 | |
| Graham number | 12.53 | 50.71 | 42.51 | 36.7 | 34.02 | |
| ROIC | 0.01 | 0.15 | 0.11 | 0.08 | 0.06 | |
| Return on tangible assets | 0.01 | 0.14 | 0.11 | 0.08 | 0.07 | |
| Graham Net | 23.14 | 25.91 | 26.78 | 26.13 | 26.1 | |
| Working capital | 3.44B | 3.99B | 3.92B | 3.85B | 3.84B | |
| Tangible asset value | 3.48B | 4.01B | 3.94B | 3.87B | 3.86B | |
| Net current asset value | 3.42B | 3.97B | 3.92B | 3.83B | 3.83B | |
| Invested capital | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Average receivables | 138.04M | 444.75M | 470.34M | 206.82M | 247.71M | |
| Average payables | 10.29M | 245.5K | 0 | 0 | 0 | |
| Average inventory | 21.83M | 24.43M | 15.09M | 19.9M | 25.14M | |
| Days sales outstanding | 161.1 | 259.54 | 105.79 | 124.86 | 129.13 | |
| Days payables outstanding | 5.64 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 276.81 | 242.51 | 53.48 | 252.46 | 119.18 | |
| Receivables turnover | 2.27 | 1.41 | 3.45 | 2.92 | 2.83 | |
| Payables turnover | 64.76 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 1.32 | 1.51 | 6.82 | 1.45 | 3.06 | |
| ROE | 0.01 | 0.15 | 0.11 | 0.08 | 0.07 | |
| Capex per share | 0 | 0 | 0 | -0.03 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.1 | 1.17 | 1.16 | 1.71 | 1.3 | |
| Net income per share | 0.37 | 0.57 | 0.52 | 0.56 | 0.26 | |
| Operating cash flow per share | 0.25 | 0.63 | 0.67 | -0.04 | 0.52 | |
| Free cash flow per share | 0.25 | 0.63 | 0.67 | -0.04 | 0.52 | |
| Cash per share | 25.5 | 26.18 | 26.83 | 24.76 | 25.26 | |
| Book value per share | 26.97 | 27.54 | 26.07 | 26.63 | 26.9 | |
| Tangible book value per share | 26.95 | 27.52 | 26.06 | 26.63 | 26.9 | |
| Share holders equity per share | 26.97 | 27.54 | 26.07 | 26.63 | 26.9 | |
| Interest debt per share | 0.16 | 0.14 | 0.13 | 0.12 | 0.1 | |
| Market cap | 17.95B | 15.51B | 14B | 12.47B | 15.8B | |
| Enterprise value | 16.2B | 13.58B | 12.01B | 10.75B | 14.94B | |
| P/E ratio | 83.69 | 47.64 | 46.6 | 38.58 | 105.69 | |
| Price to sales ratio | 113.27 | 92.13 | 84.3 | 50.69 | 84.34 | |
| POCF ratio | 498.69 | 171.61 | 144.64 | -2.32K | 210.16 | |
| PFCF ratio | 501.71 | 171.68 | 144.58 | -2.23K | 211.79 | |
| P/B Ratio | 4.64 | 3.92 | 3.74 | 3.26 | 4.09 | |
| PTB ratio | 4.64 | 3.92 | 3.74 | 3.26 | 4.09 | |
| EV to sales | 102.24 | 80.68 | 72.32 | 43.69 | 79.75 | |
| Enterprise value over EBITDA | 243.24 | 129.6 | 161.11 | 101.96 | 221.56 | |
| EV to operating cash flow | 450.17 | 150.28 | 124.08 | -2K | 198.71 | |
| EV to free cash flow | 452.89 | 150.35 | 124.03 | -1.93K | 200.25 | |
| Earnings yield | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Free cash flow yield | 0 | 0.01 | 0.01 | 0 | 0 | |
| Debt to equity | 0.01 | 0.01 | 0 | 0 | 0 | |
| Debt to assets | 0.01 | 0.01 | 0 | 0 | 0 | |
| Net debt to EBITDA | -26.22 | -18.39 | -26.69 | -16.33 | -12.77 | |
| Current ratio | 49.86 | 48.86 | 9.83 | 61.92 | 46.78 | |
| Interest coverage | 1.95K | 1.14K | 892.52 | 1.39K | 1K | |
| Income quality | 0.56 | 0.88 | 1.34 | -0.05 | 2.01 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0 | 0 | 0 | 3.56 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.14 | 0.14 | 0.1 | 0.12 | |
| Research and developement to revenue | 0.38 | 0.24 | 0.41 | 0.51 | 0.42 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.01 | 0 | 0 | 0.04 | -0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.1 | -0.02 | 0.02 | -0.09 | -0.26 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Graham number | 15.05 | 18.74 | 17.52 | 18.36 | 12.55 | |
| ROIC | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Return on tangible assets | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Graham Net | 26.13 | 26.79 | 25.22 | 25.78 | 26.1 | |
| Working capital | 3.85B | 3.93B | 3.72B | 3.8B | 3.84B | |
| Tangible asset value | 3.87B | 3.95B | 3.74B | 3.82B | 3.86B | |
| Net current asset value | 3.83B | 3.92B | 3.71B | 3.79B | 3.83B | |
| Invested capital | 0.01 | 0.01 | 0 | 0 | 0 | |
| Average receivables | 229.66M | 226.99M | 237.47M | 261.12M | 274.5M | |
| Average payables | 0 | 0 | 16.6M | 16.6M | 0 | |
| Average inventory | 40.7M | 27.5M | 29.74M | 32.96M | 21.49M | |
| Days sales outstanding | 127.13 | 123.04 | 132.67 | 101.52 | 130.48 | |
| Days payables outstanding | 0 | 0 | 236.57 | 0 | 0 | |
| Days of inventory on hand | 251.87 | 136.25 | 276.81 | 210.03 | 132.06 | |
| Receivables turnover | 0.71 | 0.73 | 0.68 | 0.89 | 0.69 | |
| Payables turnover | 0 | 0 | 0.38 | 0 | 0 | |
| Inventory turnover | 0.36 | 0.66 | 0.33 | 0.43 | 0.68 | |
| ROE | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
4162.TWO Frequently Asked Questions
What is PharmaEngine, Inc. stock symbol ?
PharmaEngine, Inc. is a TW stock and trading under the symbol 4162.TWO
What is PharmaEngine, Inc. stock quote today ?
PharmaEngine, Inc. stock price is $89 today.
Is PharmaEngine, Inc. stock public?
Yes, PharmaEngine, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.53M
- Market Capitalization 13.95B
- Employee 17
- CEO Mr. Hong-Ren Wang Ph.D.
- Headquarters Taipei,TW
- IPO Date 2012-06-20
-
Website
https://www.pharmaengine.com 
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
